• Customer Care
  • (888) 123-4567


Rise Therapeutics is recruiting a full-time microbiologist to lead its initiatives in synthetic biology at our Rockville, Maryland laboratory. This position offers a unique opportunity for an entrepreneurial minded scientist to advance the skills and experience necessary for a successful career in the biotechnology industry. The microbiology scientist will support research and development strategies that harness new microbiome discoveries to create novel and innovative synthetic biology-based medicines.

Required Qualifications

  • Degree (MS, and/or PhD) in the life sciences or biomedical engineering
  • Expertise in microbiological science
  • Strong knowledge of molecular biology techniques
  • Familiarity with bacterial fermentation
  • Strong writing skills
  • Effective communication skills with the ability to contribute in a fast-paced environment
  • Strong sense of responsibility for deadlines and data accuracy
  • Rigor and attention to detail including laboratory notebook documentation
  • Comfort with collaboration in a team-based environment

Duties and Responsibilities

  • Lead new drug development strategies for synthetic biology-based medicines
  • Develop and test novel microbiome drug candidates
  • Perform analytical testing procedures for product characterization
  • Develop new microbiology assays and scientific assessment procedures
  • Support discovery and development of new bacteria fermentation procedures
  • Author SOPs, reports, and other controlled documents important for IND filings
  • Develop methods to create novel product characterization tests


  • Support initiatives to develop novel microbiome-associated products
  • Gain experience working in biotech helping to drive new medicines into clinical testing
  • Expand relationships/connections with leading biotechnology researchers


About Rise Therapeutics

Rise Therapeutics is an emerging, privately held biotech company located in Rockville, Maryland, which develops novel synthetic biology-based medicines. As a product focused company, we leverage our proprietary drug delivery platform and GMP manufacturing infrastructure to create targeted immunologically-directed Live Biotherapeutic Products (LBPs). Rise harnesses novel discoveries in microbiome biology as it relates to regulation of immune function to identify new immune regulatory pathways and develop unique, first-in-class immune modulatory drugs for the treatment of autoimmunity, inflammation, infection, and cancer. For more information, please visit our website at www.risetherapeutics.com.


Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Title document as "last name first inital-title of position-resume.pdf" e.g. "DoeJ-Microbiologist-resume.pdf"

Our News

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

Rockville, MD. Rise Therapeutics, a company that develops innovative immune therapies, announced today that it initiated a new program to develop a novel, immunologically enhanced microbiome drug for the treatment of cancer. This product candidate, R-5780, engages key immune pathways regulated by the microbiome to enhance the effectiveness of immune checkpoint inhibitor (ICI) therapy to treat cancer. Coinciding with the timing of this release, Rise has secured funding to support key product development initiatives for the program.

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.